- PR Newswire•3 hours ago
SAN DIEGO, April 25, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced its intention to offer, subject to market and other conditions, $450.0 million aggregate principal amount of convertible senior notes due 2024 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The notes will be senior unsecured obligations of Neurocrine and will accrue interest payable semiannually in arrears. The notes will be convertible in certain circumstances into cash, shares of Neurocrine's common stock, or a combination of cash and shares of Neurocrine's common stock, at Neurocrine's election.
- Benzinga•5 hours ago
Investment in biotech stocks is fraught with risks. These stocks trade in anticipation of some "make-or-break" events called catalysts and therefore face the danger of seeing wild swings in the ...
- PR Newswire•5 days ago
Neurocrine Announces INGREZZA™ Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting
SAN DIEGO, April 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that long-term safety and efficacy data from the KINECT 3 Phase III extension study of INGREZZA™ (valbenazine) capsules for the treatment of adults with tardive dyskinesia will be presented as a platform presentation at the American Academy of Neurology (AAN) Annual Meeting April 22-28, 2017 in Boston. Additionally, two posters representing additional data from several clinical trials of INGREZZA will be presented, including an analysis of its pharmacologic characteristics. "We are very pleased to present additional robust data from the largest ever clinical program in tardive dyskinesia at this year's American Academy of Neurology Annual Meeting," said Chris O'Brien, M.D., FAAN, Chief Medical Officer at Neurocrine.
NBIX : Summary for Neurocrine Biosciences, Inc. - Yahoo Finance
Neurocrine Biosciences, Inc. (NBIX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||51.52 x 500|
|Ask||53.75 x 100|
|Day's Range||51.95 - 53.85|
|52 Week Range||37.35 - 55.15|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-32.90|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|